Abstract
Background
The present study aimed to assess the short-term consequences of biportal robot-assisted lobectomy, validating its safety and effectiveness.
Methods
A retrospective analysis evaluated the clinical data and short-term results of 18 patients in the single medical group of the center who underwent biportal robot-assisted lobectomy plus lymph node dissection from November 2020 to March 2021.
Results
Lobectomy and lymph node dissection could be successfully accomplished in all 18 patients with the assistance of a biportal robot; there was no conversion to thoracotomy during the operation. There were ten males and eight females with their ages ranging from 37 to 73 (58.83 ±9.07) years. The total operation time was 74–146 (105.06 ±18.22) min. Punching time was 2–9 (5.11 ±1.74) min. Docking time was 8–16 (11.94 ±2.41) min. Console time was 50–104 (78.06 ±17.40) min. Chest closing time was 8–17 (10.28 ±2.74) min. Blood loss was 60–132 (94.11 ±41.41) ml. The number of lymph nodes dissected was 16–30 (21.78 ±4.13). Chest tube duration was 2–10 (4.06 ±1.98) d. Drainage on the first day following surgery was 100–500 (337.22 ±117.01) ml. Total drainage was 370–1100 (692.78 ±161.01) ml. Duration of hospital stay was 4–12 (5.89 ±1.94) d. The median 24 h and 72 h VAS scores were 4 (3–7) and 3 (2–5). Total cost (￥) was 51000-85000 (68000±10000), res pectively. There was 1 case of atrial fibrillation, and 1 case of pulmonary infection. The complication rate was 11.11%. No serious complications were recorded after surgery, and no deaths occurred within 30 days post-surgery. The final pathological diagnosis revealed 10 cases of squamous cell carcinoma, 7 cases of adenocarcinoma, and 1 case of benign disease.
Conclusion
The biportal robot-assisted lobectomy was found to be safe and effective in the treatment of lung cancer.
This article is protected by copyright. All rights reserved.
No comments:
Post a Comment